Fig. 3From: Dose selection for glycopyrrolate/eFlow® phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studiesMean change from baseline in FEV1 over time on Day 7 (pooled population). BID, twice daily. FEV1, forced expiratory volume in 1 secondBack to article page